Items per page
Sort by

Send to:

Choose Destination

Results: 6


Recognition of mesothelin by the therapeutic antibody MORAb-009: structural and mechanistic insights.

Ma J, Tang WK, Esser L, Pastan I, Xia D.

J Biol Chem. 2012 Sep 28;287(40):33123-31. Epub 2012 Jul 11.


The role of mesothelin in tumor progression and targeted therapy.

Tang Z, Qian M, Ho M.

Anticancer Agents Med Chem. 2013 Feb;13(2):276-80. Review.


Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody.

Shin IS, Lee SM, Kim HS, Yao Z, Regino C, Sato N, Cheng KT, Hassan R, Campo MF, Albone EF, Choyke PL, Pastan I, Paik CH.

Nucl Med Biol. 2011 Nov;38(8):1119-27. doi: 10.1016/j.nucmedbio.2011.05.003. Epub 2011 Jul 7.


Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.

Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D.

Clin Cancer Res. 2010 Dec 15;16(24):6132-8. doi: 10.1158/1078-0432.CCR-10-2275. Epub 2010 Oct 29.


Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.

Hassan R, Schweizer C, Lu KF, Schuler B, Remaley AT, Weil SC, Pastan I.

Lung Cancer. 2010 Jun;68(3):455-9. doi: 10.1016/j.lungcan.2009.07.016. Epub 2009 Sep 9.


Mesothelin targeted cancer immunotherapy.

Hassan R, Ho M.

Eur J Cancer. 2008 Jan;44(1):46-53. Epub 2007 Oct 22. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk